Alzheimer’s drug approved for dispensing

Share this article with friends

EmailEmail Copy LinkCOPY

KISUNLA (donanemab), a new Alzheimer’s treatment, has been approved in Australia for early-stage patients with a specific genetic profile and confirmed amyloid plaque build-up. It’s the first treatment in 25 years to target the disease’s cause by clearing brain plaques. Administered monthly, Kisunla aims to preserve independence longer. With 450,000 Australians in early stages potentially eligible, the drug’s PBS listing will be reviewed in July. Experts call it a breakthrough and urge support for early detection and access.

Article Details

Published in

Editors Picks